Back to Gastroenterology


Non-Alcoholic Steatohepatitis & Non-Alcoholic Fatty Liver Disease

Non-Alcoholic Steatohepatitis & Non-Alcoholic Fatty Liver Disease Market Research

What is Non-Alcoholic Steatohepatitis (NASH) & Non-Alcoholic Fatty Liver Disease (NAFLD)?

Non-alcoholic steatohepatitis (NASH) is an advanced form of nonalcoholic fatty liver disease (NAFLD). NAFLD is caused when fat builds up in the liver, causing symptoms such as fatigue and abdominal discomfort, though generally speaking, it can be difficult to diagnose until it has progressed, as it can be a silent disease. As the disease progresses into NASH, patients may have more distinctive symptoms, such as loss of appetite, weight loss, itchy skin, confusion, and jaundice. Patients may also find that they bruise and bleed easily. NAFLD manifests to NASH as the fat in the liver builds up, causing inflammation and scarring, or fibrosis, to the liver. If fibrosis progresses, it can lead to a condition called cirrhosis, in with the liver is irreparably damaged; the condition can be life-threatening. Currently, there is no FDA-approved NASH therapeutic on the market, though there are currently pipeline therapeutics undergoing trials to gain approval and enter this untapped market. Besides potential new treatments that may be on the horizon, physicians recommend lifestyle changes in order to slow the disease’s progression. These changes include: reducing/eliminating the consumption of alcohol (as alcohol can become a contributing factor), maintaining a healthy diet, treating underlying conditions (such as hypothyroidism), and losing weight for patients who may be overweight.

Spherix Global Insights – Gastroenterology – NASH & NAFLD

Spherix Global Insights’ Gastroenterology therapeutic team is a leading provider of independent NASH & NAFLD market research, insights, business intelligence & advisory services.

On an annual basis, Spherix’s Gastroenterology team publishes four (4) studies covering NASH and NAFLD including:

• Market Dynamix™: Nonalcoholic Fatty Liver Disease/Non-Alcoholic Steatohepatitis (US)
• Launch Dynamix: Lanifibranor (Inventiva) in Nonalcoholic Fatty Liver Disease*
• Launch Dynamix™: Resmetirom (Madrigal) in Nonalcoholic Fatty Liver Disease*

*Pending approvals and launch

Spherix’s Launch Dynamixservice consists of two parts: monthly KPI tracking and quarterly deep dives. Monthly KPIs provide monthly benchmarking of newly launched products for the first eighteen months of commercial availability, and quarterly deep dive reports covering promotional activity, barriers to uptake, and patient types being identified for the launch brand.

Spherix’s Market Dynamix™ service includes analysis of markets anticipated to experience a paradigm shift within the next three to five years. Its insights highlight market size, current treatment approaches, unmet needs, and expert opinions on the likely disruption introduced by pipeline agents.

Follow Spherix Gastroenterology on Social Media
Follow us for gastroenterology industry news, insights & analysis:


For Guests & Current Clients

For more details on Spherix’s primary market research reports and interactive dashboard offerings, visit or register here:


Get more information on Irritable Bowel Syndrome Coverage